DUBLIN–(BUSINESS WIRE)–The “Non-alcoholic Steatohepatitis Biomarkers Market Analysis by Type (Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis), by End User (Hospitals, Pharmaceutical & CRO Industry, Diagnostic Labs), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The global non-alcoholic steatohepatitis biomarkers market size is estimated to be USD 537.1 million in 2021 and is expected to witness a CAGR of 31.89% during the forecast period.
Increasing prevalence of chronic diseases such as heart disease, cancer, and diabetes is a key driver for the growth of the global non-alcoholic steatohepatitis biomarkers market.
Additionally, demand for non-invasive diagnostics methods for NASH biomarkers, rising investment by government and private organizations in R&D for NASH biomarkers therapeutics are some of the other drivers propelling the market growth.
Nevertheless, side-effects and risks associated with NASH therapeutics and the high cost of technology are expected to restrain the global market growth.
By Type
Based on type, the market is segmented into hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and other types.
In 2021, the serum biomarkers segment accounted for a substantial revenue share and is expected to grow with a profitable CAGR during the forecast period.
This is attributed to associated benefits of serum biomarkers such as the ability to distinguish simple steatosis from NASH and efficient outcomes worldwide. Oxidative stress biomarkers segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the growth in incidence of diabetes & obesity globally and the improvement in awareness of NASH in developing regions.
By End User
Based on end user, the market is segmented into hospitals, pharma & CRO Industry, diagnostics labs, and academic research institutes.
In 2021, the pharma & CRO Industry segment accounted for a substantial revenue share and is expected to grow with a profitable CAGR during the forecast period. This is attributed to the growing demand for non-invasive NASH diagnostic & monitoring tools in the ongoing clinical trials by CROs and pharmaceutical manufacturers can be attributed to its strong growth worldwide.
The hospitals segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to increasing in funding to hospitals by the government as well as private players to conduct research on non-alcoholic steatohepatitis biomarkers.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the favorable government initiatives regarding technological development of biomarkers and rising prevalence of infectious and chronic diseases, cardiovascular diseases, & cancer in the region.
Asia Pacific market is projected to grow at the fastest CAGR over the forecast period owing to the large population base, improved medical facilities, and presence of huge future growth opportunities in this region.
Competitor Insights
Investment in R&D, novel product launches, and strategic collaborations & acquisitions are some of the major strategies adopted by the leading players operating in the industry.
Company Profiles
- GENFIT (France)
- Gilead (U.S.)
- AstraZeneca (U.K.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb (U.S)
- Allergan Novo Nordisk A/S (Ireland)
- Boehringer Ingelheim GmbH (Germany)
- Pfizer Inc. (U.S.)
- Cadila Healthcare Ltd. (India)
- Conatus Pharmaceuticals Inc. (U.S.)
Scope of the Report
Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Revenue, 2021-2029, USD Million)
- Hepatic Fibrosis Biomarkers
- Serum Biomarkers
- Oxidative Stress Biomarkers
- Apoptosis Biomarkers
- Others
Non-alcoholic Steatohepatitis Biomarkers Market, By End User (Revenue, 2021-2029, USD Million)
- Hospitals
- Pharma & CRO Industry
- Diagnostic Labs
- Academic Research Institutes
Non-alcoholic Steatohepatitis Biomarkers Market, By Region (Revenue, 2021-2029, USD Million)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
For more information about this report visit https://www.researchandmarkets.com/r/sg5w9g
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900